Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 24th Preview)
-
Gene therapy safety—FDA pauses Regenxbio Hunter syndrome program
FDA again paused trials for Regenxbio’s Hunter syndrome gene therapy after safety findings tied to spine MRI abnormalities in five treated patients, according to the company’s disclosure and STAT+ reporting. The FDA’s action blocks Regenxbio’s near-term plan to refile for approval of RGX-121 (clemidsogene lanparvovec). The latest clinical hold follows an earlier stop ordered this year, compounding scrutiny of AAV-based spine-administered gene therapies. Regenxbio said the patients were asymptomatic despite the imaging masses detected, but the agency is requiring additional review before further enrollment or regulatory progress. Separately, reporting indicates the program’s resubmission plans have been derailed by the FDA’s hold over spine MRI findings, leaving uncertainty around timing for any future BLA submission. For the broader field, the case underscores how spinal imaging findings can trigger regulatory pauses even absent clear clinical symptoms.
-
Obesity deals—Roche locks in Hanmi muscle-sparing asset
Roche secured rights to Hanmi Pharmaceutical’s obesity drug candidate designed to increase muscle mass while reducing fat, the company disclosed via a deal reported in industry coverage. Roche will pay $190 million upfront, with total consideration potentially reaching $2.3 billion as the parties develop and commercialize the therapy. The asset activates a receptor in skeletal muscle and targets a different mechanism than Roche’s other obesity pipeline entries. Terms exclude South Korea, where Hanmi is based, and outline global development responsibilities across the licensed territory. The agreement adds to Roche’s recent pattern of obesity partnerships, but it also signals an emphasis on differentiating beyond incretin biology by pursuing lean-mass preservation alongside weight loss.
-
Alzheimer’s diagnostics—FDA clears Roche/Lilly blood-based biomarker test
Roche and Eli Lilly received U.S. FDA clearance for Elecsys Phospho-Tau (217P) Plasma, a blood test intended to identify amyloid pathology associated with Alzheimer’s disease. The assay targets individuals 55 and older who present with signs, symptoms or complaints of cognitive decline. The clearance adds to the growing set of plasma biomarker tests used to support earlier identification of underlying Alzheimer’s biology. It also broadens the diagnostic toolkit beyond cerebrospinal fluid biomarkers and imaging. By bringing another blood-based marker into the U.S. market, the companies position their test for clinical workflows where clinicians need a scalable method to evaluate amyloid-associated disease.
-
Device approval—FDA grants humanitarian approval to Oncosil brachytherapy
The U.S. FDA awarded a humanitarian device exemption (HDE) approval to Oncosil Medical’s Oncosil brachytherapy device for distal cholangiocarcinoma, according to the company’s disclosure. Oncosil said it becomes the first and only U.S. FDA-approved Class III device for this rare bile duct cancer indication. HDE pathways are designed for conditions affecting small patient populations, typically providing limited commercial use while still requiring safety and performance evidence. The approval gives clinicians an additional procedural option for dCCA. For Oncosil, the clearance represents a regulatory milestone that may accelerate adoption and investment as the company supports further evidence generation in an area with few targeted options.
-
Cell therapy regulatory clock—FDA extends review for Capricor deramiocel
The FDA extended its review of Capricor Therapeutics’ deramiocel, pushing the PDUFA decision timeline as the agency seeks additional information for a refined indication. Capricor said the regulator is reviewing updated data tied to the therapy’s use profile. The delay continues a high-attention regulatory sequence for deramiocel, with prior comments around clinical and label scope drawing scrutiny. Capricor’s updates aim to address the FDA’s requests and better define where the therapy may fit clinically. From an industry perspective, the extended review highlights how label refinements and new datasets can materially shift cell therapy review timelines and commercial planning.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.